NKGen Biotech administers first dose of troculeucel for FTD under FDA-cleared compassionate use
NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in natural killer cell therapy, has taken a significant step in the treatment of frontotemporal ... Read More
MiraDx to enroll patients for non-tumor based microRNA clinical trial
MicroRNA clinical trial : MiraDx, a Los Angeles-based molecular genetics company, has initiated patient enrollment in collaboration with UCLA for the non-tumor based microRNA biomarker-driven ... Read More